Clinical Trials Logo

Rhinitis, Allergic clinical trials

View clinical trials related to Rhinitis, Allergic.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06372184 Not yet recruiting - Rhinitis, Allergic Clinical Trials

Washed Microbiota Transplantation for Allergic Rhinitis

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

NCT ID: NCT06339008 Not yet recruiting - Clinical trials for Perennial Allergic Rhinitis (PAR)

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Start date: April 12, 2024
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months

NCT ID: NCT06330974 Not yet recruiting - Asthma Clinical Trials

Allergy, Asthma, and Atopic Eczema in Finland

FinnATOPY
Start date: October 2024
Phase:
Study type: Observational [Patient Registry]

The summary is available at --> https://www.finnatopy.fi/summary

NCT ID: NCT06315426 Not yet recruiting - Allergic Rhinitis Clinical Trials

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Start date: March 2024
Phase: Phase 2
Study type: Interventional

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

NCT ID: NCT06300203 Not yet recruiting - Clinical trials for Seasonal Allergic Rhinitis

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

MEGREZ
Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

NCT ID: NCT06272409 Not yet recruiting - Allergic Rhinitis Clinical Trials

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

SIERRA
Start date: February 15, 2025
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years.

NCT ID: NCT06171074 Not yet recruiting - Clinical trials for Seasonal Allergic Rhinitis

Study of CM310 in Subjects With Seasonal Allergic Rhinitis

Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.

NCT ID: NCT05908721 Not yet recruiting - Allergic Rhinitis Clinical Trials

Study of CM310 in Patients With Allergic Rhinitis

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.

NCT ID: NCT05720455 Not yet recruiting - Rhinitis Allergic Clinical Trials

Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

FAST
Start date: July 21, 2024
Phase: Phase 4
Study type: Interventional

This is a single group, Phase IV clinical trial to assess the safety and effectiveness of Allegra® D. This study will be conducted in participants with allergic rhinitis who are 12 years of age and above. The individual study duration for each participant would be approximately 16 days (maximum of 13 days intervention + a 3-day post intervention observation). There would be 4 study visits in which the last visit can be done either telephonically or on site. Safety events would be captured for the entire study duration. In addition, the effectiveness of the study drug would be assessed using Nasal symptom score (NSS) and Total symptom score (TSS).

NCT ID: NCT05684380 Not yet recruiting - Allergic Rhinitis Clinical Trials

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Start date: September 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.